Notify me when GMS Ventures & Investments files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | Common Stock, par value $0.01 per share | 50% | $45,303,849 | +$20,057,142 | 29,040,929 | +79% | GMS VENTURES & INVESTMENTS | 27 May 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|